The Vanguard Group, Inc. recently announced the acquisition of new stake in GoodRx Holdings Inc. (NASDAQ:GDRX). The institutional investor has increased its shareholding in the Healthcare company by 7.25% to 8.32 million shares with purchase of 0.56 million shares. This fresh investment now brings its stake to 10.09% valued currently at $44.0 million. In addition, Millennium Management LLC raised its holdings by 3.2 million to 5.32 million shares. And Petrus Securities LP has lifted its position by 12.89% or 0.28 million shares – to 2.44 million shares.
With over 3.22 million GoodRx Holdings Inc. (GDRX) shares trading Friday and a closing price of $5.76 on the day, the dollar volume was approximately $18.57 million. The shares have shown a negative half year performance of -10.84% and its price on 03/10/23 gained nearly 4.92%. Currently, there are 411.67M common shares owned by the public and among those 75.59M shares have been available to trade.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 21 analysts who have offered their price forecasts for GDRX have a consensus price objective of $6.89. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $6.00. The average price target is 16.88% above its recent price level and an upside to the estimated low will see the stock gain 4.0% over that period. But an upside of 36.0% will see the stock hit the forecast high price target while median target price for the stock is $6.75.
Insiders at the company have transacted a total of 24 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 14 of these insider trades were purchases, accounting for 602,045 shares. Insider sales of the common stock occurred on 10 occasions, with total insider shares sold totaling 186,886 shares.
The top 3 mutual fund holders in GoodRx Holdings Inc. are Vanguard Total Stock Market Index, Vanguard Small Cap Index Fund, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 2.33 million shares of the company’s stock, all valued at over $12.34 million. Vanguard Small Cap Index Fund bought 9916.0 shares to see its total holdings expand to 1.82 million shares valued at over $9.61 million and representing 2.20% of the shares outstanding. Vanguard Extended Market Index Fu sold 225.0 shares to bring its total holdings to over 1.05 million shares at a value of $5.54 million. Vanguard Extended Market Index Fu now owns shares totaling to 1.27% of the shares outstanding.
Shares of GoodRx Holdings Inc. (NASDAQ: GDRX) opened at $5.54, up $0.05 from a prior closing price of $5.49. However, the script later moved the day high at 5.81, up 4.92%. The company’s stock has a 5-day price change of -2.70% and 15.66% over the past three months. GDRX shares are trading 23.61% year to date (YTD), with the 12-month market performance down to -62.93% lower. It has a 12-month low price of $3.82 and touched a high of $20.59 over the same period. GDRX has an average intraday trading volume of 1.65 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.80%, 9.37%, and 0.52% respectively.
Institutional ownership of GoodRx Holdings Inc. (NASDAQ: GDRX) shares accounts for 69.50% of the company’s 411.67M shares outstanding. Mutual fund holders own 20.51%, while other institutional holders and individual stakeholders account for 41.24% and 14.96% respectively.
It has a market capitalization of $2.18B. The earnings-per-share (ttm) stands at -$0.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.82% over the week and 5.40% over the month.
Analysts forecast that GoodRx Holdings Inc. (GDRX) will achieve an EPS of $0.05 for the current quarter, $0.05 for the next quarter and $0.26 for 2023. The lowest estimate earnings-per-share for the quarter is $0.03 while analysts give the company a high EPS estimate of $0.05. Comparatively, EPS for the current quarter was $0.09 a year ago. Earnings per share for the fiscal year are expected to decrease by -29.10%, and 25.10% over the next financial year. EPS should grow at an annualized rate of 2.14% over the next five years, compared to -25.10% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 21 brokerage firm advisors rate GoodRx Holdings Inc. (GDRX) as a “Moderate Buy” at a consensus score of 2.60. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 17 of the 21 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the GDRX, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on December 01, 2022, with the firm’s price target at $7. JP Morgan coverage for the GoodRx Holdings Inc. (GDRX) stock in a research note released on November 04, 2022 offered a Neutral rating with a price target of $8. KeyBanc Capital Markets was of a view on September 16, 2022 that the stock is Sector Weight, while Truist gave the stock Hold rating on September 07, 2022, issuing a price target of $6.50. DA Davidson on their part issued Neutral rating on August 12, 2022.
Leave a Reply